3.995
0.51%
0.065
アフターアワーズ:
3.80
-0.195
-4.88%
前日終値:
$3.93
開ける:
$4.02
24時間の取引高:
1,184
Relative Volume:
0.14
時価総額:
$186.30M
収益:
$27,600
当期純損益:
$-36.04M
株価収益率:
-2.2543
EPS:
-1.7722
ネットキャッシュフロー:
$-1.66M
1週間 パフォーマンス:
-2.47%
1か月 パフォーマンス:
-16.49%
6か月 パフォーマンス:
-45.37%
1年 パフォーマンス:
-35.40%
Nanobiotix Adr Stock (NBTX) Company Profile
NBTX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
NBTX | 3.995 | 186.30M | 27,600 | -36.04M | -1.66M | -1.7722 |
VRTX | 467.12 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.38 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Nanobiotix Adr Stock (NBTX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2021-01-06 | 開始されました | Evercore ISI | Outperform |
Nanobiotix Adr (NBTX) 最新ニュース
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewswire Inc.
Nanobiotix (NASDAQ:NBTX) Trading Down 14% - Defense World
Nanobiotix (NASDAQ:NBTX) Stock Price Down 14% - MarketBeat
Nanobiotix S.A. (NASDAQ:NBTX) Forecasted to Earn FY2025 Earnings of $0.88 Per Share - MarketBeat
Earnings call: Nanobiotix reports Q1 2024 results, advances with NBTXR3 - Investing.com India
Earnings call: Nanobiotix reports Q1 2024 results, advances with NBTXR3 By Investing.com - Investing.com
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in ... - The Globe and Mail
Nanobiotix Announces Latest Share and Voting Rights UpdateTipRanks.com - TipRanks
Nanobiotix Prepares to Unveil Q1 2024 ResultsTipRanks.com - TipRanks
Nanobiotix's NBTXR3 Enters Phase 2 Lung Cancer StudyTipRanks.com - TipRanks
Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen PartnershipTipRanks.com - TipRanks
Nanobiotix Sa ADR Updates Share Capital InfoTipRanks.com - TipRanks
Nanobiotix Advances NBTXR3 for Lung Cancer TreatmentTipRanks.com - TipRanks
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022 - The Globe and Mail
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC ... - The Globe and Mail
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure - Business Wire
NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive ... - The Globe and Mail
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets - Business Wire
IPO Launch: Nanobiotix S.A. Pursues $96 Million IPOIPOs On TheStreetU.S. IPO Research & Opinion - TheStreet
NBTX News Today | Why did Nanobiotix stock go down today? - MarketBeat
Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat
Nanobiotix - Massachusetts Biotechnology Council
Nanobiotix Adr (NBTX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):